Peripheral Circulating Exosomes Induce Sepsis-associated Liver Injury by Up-regulating STAT1 to Promote Autophagy and Regulating the SLC7A11-GSH-GPX4 Axis to Promote Ferroptosis Authors: Yu-Jia Tang, Xue Du, Bing Yin, Hui-Ying Liu, Yi-Jin Tang, Zi-Yue Zhang, Qing-Min Meng, Yan Zhang, Jia-Le Deng, Yao Li, Pei-Lin Yang, Kai Kang, Ming-Yan Zhao, Yang Gao Published: 2026 ABSTRACT AbstractPeripheral exosomes have been implicated in the pathogenesis of multiple organ dysfunction during sepsis. However, their role in sepsis-associated liver injury (SALI) remains unclear. This study aimed to investigate the effects of circulating exosomes on hepatic injury and to elucidate the underlying molecular mechanisms of SALI. A murine sepsis model was established via intraperitoneal injection of lipopolysaccharide (LPS). Peripheral exosomes were isolated and co-cultured with murine hepatocytes (AML12 cells). RNA sequencing identified Signal transducer and activator of transcription 1 (STAT1) as a key regulator in exosome-induced liver injury. Since STAT1 functions upstream of the ferroptosis-related solute carrier family 7 member 11 (SLC7A11)–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis, further in vivo and in vitro experiments were conducted to clarify its mechanistic role. In vitro, exosomes derived from septic mice enhanced inflammatory responses in AML12 cells via STAT1-mediated autophagy and modulation of the SLC7A11–GSH–GPX4 axis, leading to ferroptosis. Inhibition of STAT1 abrogated these effects, whereas STAT1 overexpression potentiated them. In vivo, septic exosomes (sep-Exo) induced liver injury in mice, while suppression of STAT1 abolished the regulatory effects of sep-Exo on ferroptosis, autophagy, and hepatic inflammation. Our findings reveal a novel mechanism underlying SALI, whereby peripheral exosomes upregulate STAT1 to induce autophagy and modulate the SLC7A11–GSH–GPX4 axis, thereby promoting ferroptosis and hepatic inflammation during sepsis.Graphical Abstract Peripheral circulating exosomes induce SALI by upregulating STAT1 to promote autophagy and modulating the SLC7A11-GSH-GPX4 axis to induce ferroptosis Supplementary InformationThe online version contains supplementary material available at 10.1007/s10753-026-02495-6.Keywords: Exosome, STAT1, Sepsis-associated liver injury, Ferroptosis, Autophagy Introduction Sepsis is a life-threatening syndrome characterized by dysregulated host responses to infection, leading to acute and progressive organ dysfunction [1]. It remains one of the leading causes of morbidity and mortality worldwide [2]. Despite advances in early antibiotic administration, fluid resuscitation, and multi-organ support strategies, the overall prognosis for patients with sepsis remains unsatisfactory [3]. Therefore, elucidating the cellular and molecular mechanisms underlying sepsis-induced organ injury is essential for improving clinical outcomes. The liver plays a pivotal role in metabolism and immune regulation, contributing to energy storage, detoxification, coagulation, and hormonal homeostasis [4]. Increasing evidence suggests that hepatic dysfunction is a common and severe complication of sepsis, significantly influencing disease progression and patient prognosis [5]. As a frontline immune organ, the liver is often among the first organs affected during sepsis and frequently exhibits severe injury [6]. Excessive microbial burden and the ensuing cytokine storm can trigger hyperactivation of inflammatory pathways, leading to disruption of homeostasis and hepatocellular death [7, 8]. Clinically, the mortality rate in septic patients with hepatic dysfunction has been reported to range from 54% to 68% [4], underscoring the urgent need to elucidate the molecular mechanisms underlying sepsis-associated liver injury (SALI). Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a critical contributor to multiple organ failure during sepsis. The solute carrier family 7 member 11 (SLC7A11)–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis represents a core antioxidant defense system that protects cells from oxidative stress-induced ferroptosis. Dysregulation of this pathway may accelerate the progression of septic organ injury. Given the liver’s essential role in iron storage and metabolism, hepatocytes are particularly susceptible to ferroptotic death under conditions of iron overload. Excessive accumulation of free iron can exacerbate oxidative damage and impair hepatic function, particularly under lipopolysaccharide (LPS)-induced inflammatory stress. Although several studies have linked ferroptosis to sepsis pathophysiology [9, 10], the upstream molecular mechanisms initiating this process remain poorly understood. Exosomes, nanosized extracellular vesicles secreted by a wide range of cell types, including platelets, endothelial cells, and smooth muscle cells [11], are key mediators of intercellular communication. They transport bioactive molecules such as lipids, proteins, and nucleic acids, thereby regulating the biological behavior of recipient cells [12]. Growing evidence indicates that exosomes play crucial roles in both local and systemic inflammatory responses. In septic mouse models, serum-derived exosomes promote macrophage proliferation and inflammatory activation [13], while neutrophil-derived exosomes deliver miR-30-5p to induce macrophage polarization and pyroptosis [14]. These findings suggest that exosomes actively participate in the pathogenesis of sepsis; however, their specific contribution to SALI remains incompletely understood. Signal transducer and activator of transcription 1 (STAT1), a member of the STAT transcription factor family, is a key downstream effector of the interferon-mediated Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling pathway [15]. Upon activation, STAT1 translocates to the nucleus and binds specific DNA elements to regulate gene expression. During inflammatory responses, STAT1 directly interacts with the HMGB1 promoter (− 1700 to − 700 bp), thereby enhancing transcription of this late inflammatory mediator [16]. Elevated STAT1 activity has been observed in septic patients, where it acts as a central signaling hub integrating multiple inflammatory pathways to amplify cytokine production [17]. However, whether STAT1 functions as a critical molecular link between circulating exosomes and ferroptosis-mediated hepatic injury in sepsis remains unclear. Based on these observations, we hypothesized that peripheral circulating exosomes contribute to SALI by modulating the STAT1 signaling pathway. To test this hypothesis, we established an LPS-induced murine sepsis model and isolated circulating exosomes from septic mice. Through a series of in vitro and in vivo experiments, we demonstrated that these exosomes induce hepatocyte injury, promote autophagy, and trigger ferroptosis. RNA sequencing further identified STAT1 upregulation as a pivotal event in this process. Mechanistic analyses revealed that peripheral circulating exosomes induce autophagy and ferroptosis via STAT1-dependent regulation of the SLC7A11–GSH–GPX4 axis. Collectively, this study uncovers a novel pathological pathway through which circulating exosomes mediate SALI, providing new insights into potential therapeutic strategies for sepsis. Materials and Methods Patients and Control Subjects The study protocol, procedures, and recruitment of patients and control subjects were approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University, China (IACUC No. IRB-AF/SC-04/02.0). Written informed consent was obtained from all participants prior to enrollment. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Clinical trial number: IRB number: LC2024-058. A total of 80 patients admitted to the Department of Critical Care Medicine at the First Affiliated Hospital of Harbin Medical University were enrolled between March 2022 and May 2023, including 40 patients diagnosed with SALI and 40 septic patients without liver injury. Blood samples and clinical data were collected upon admission. The diagnosis of sepsis was established according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Inclusion criteria were as follows: Adult patients meeting the Sepsis-3 diagnostic criteria; Adult patients meeting the Sepsis-3 diagnostic criteria; Liver injury defined by at least one of the following parameters:Total bilirubin (TBIL) > 34.2 µmol/L;Alanine aminotransferase (ALT) > 120 U/L;Aspartate aminotransferase (AST) > 120 U/L. Liver injury defined by at least one of the following parameters:Total bilirubin (TBIL) > 34.2 µmol/L;Alanine aminotransferase (ALT) > 120 U/L;Aspartate aminotransferase (AST) > 120 U/L. Total bilirubin (TBIL) > 34.2 µmol/L; Total bilirubin (TBIL) > 34.2 µmol/L; Alanine aminotransferase (ALT) > 120 U/L; Alanine aminotransferase (ALT) > 120 U/L; Aspartate aminotransferase (AST) > 120 U/L. Aspartate aminotransferase (AST) > 120 U/L. Exclusion criteria included pregnancy, a history of malignancy, drug-induced liver injury, chronic liver disease, autoimmune or metabolic liver disorders, acute liver failure, immunosuppressive or immunodeficiency conditions, and incomplete clinical data that could interfere with statistical analysis. In addition, 20 healthy adult volunteers were recruited from the local community in Harbin as healthy controls. The expression levels of exosome-specific markers, including CD63, CD9, and TSG101, were quantitatively measured using enzyme-linked immunosorbent assay (ELISA) kits. Lactate dehydrogenase (LDH) levels were obtained from routine laboratory test results, and their correlations with serum AST and ALT levels in patients with SALI were further analyzed. Animal Model Male wild-type C57BL/6 mice (6–8 weeks old, weighing 18–25 g) were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All mice were maintained under specific pathogen-free (SPF) conditions in the Hulan Laboratory Animal Center of the First Affiliated Hospital of Harbin Medical University, with controlled temperature (22 ± 2 °C), humidity (55 ± 10%), and a 12-hour light/dark cycle, and were provided ad libitum access to food and water. All animal procedures, including the establishment of the sepsis model and euthanasia, were approved by the Institutional Animal Care and Use Committee of Harbin Medical University (IACUC No. 2021100) and conducted in accordance with the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health. Cell Culture The murine hepatocyte cell line AML12 cells was obtained from Procell Life Science & Technology Co., Ltd. (Wuhan, China). Cells were cultured in complete AML12 growth medium consisting of a 1:1 mixture of Dulbecco’s Modified Eagle Medium and Ham’s F12 (DMEM/F12; ATCC 30-2006) supplemented with 10% fetal bovine serum (FBS; ATCC 30-2020), 10 µg/mL insulin, 5.5 µg/mL transferrin, 5 ng/mL selenium, and 40 ng/mL dexamethasone. Cells were maintained at 37 °C in a humidified incubator with 5% CO₂. LPS-induced Mouse Model of SALI Male SPF C57BL/6 mice were fasted for 12 h with free access to water, followed by water deprivation for 6 h prior to the experiment. All animals were weighed before the start of the experiment. Mice in the control group received intraperitoneal injections of phosphate-buffered saline (PBS). Mice in the experimental group were intraperitoneally injected with LPS (Thermo Fisher Scientific, USA) dissolved in PBS to induce SALI. The final concentration of the solution was 1.5 mg/mL, corresponding to an LPS dose of 15 mg/kg body weight per mouse. GW4869 (2.5 mg/kg; CM01341, Proteintech, China) was administered intraperitoneally 1 h prior to LPS or PBS injection as pretreatment. Twenty-four hours later, all mice were euthanized by intraperitoneal injection of an overdose of pentobarbital sodium (100 mg/kg). Blood samples were collected into EDTA-containing tubes, and liver tissues were harvested for subsequent histological analysis. Histological Analysis of Liver Tissues Liver samples were fixed in 4% paraformaldehyde (P0099-3 L, Beyotime, China) for 24 h, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Histopathological changes were examined using a light microscope. Measurement of Serum and Cellular AST and ALT Levels AST and ALT were determined using commercial assay kits (AKAM006M and AKAM019M, Boxbio, China) according to the manufacturer’s protocols. For cellular assays, AML12 cells were harvested by centrifugation at 800×g for 5 min at room temperature. Approximately 5 × 10⁶ cells were lysed in 1 mL extraction buffer and sonicated on ice (20% power, 3 s on/10 s off, for 30 cycles). The lysates were then centrifuged at 8,000×g for 10 min at 4 °C, and the supernatants were collected for analysis. For liver tissue assays, 0.1 g of liver tissue was homogenized in 1 mL extraction buffer and centrifugation at 8,000×g for 10 min at 4 °C. The resulting supernatant was used for enzymatic assays. The reactions were performed in 96-well plates by sequentially adding reagents according to the manufacturer’s instructions, followed by incubation at 37 °C. Absorbance was measured at 505 nm using a microplate reader, and AST and ALT levels were calculated based on the manufacturer’s formulas. ELISA Serum levels of exosome markers, including CD63 (ml105153, Mlbio, China), CD9 (CSB-EL004969HU, Cusabio, China), and TSG101 (ml105672, Mlbio, China) were quantified in clinical samples. Levels of inflammatory cytokines interleukin-1β (IL-1β; ml058059, Mlbio, China) and interleukin-18 (IL-18; ml058055, Mlbio, China) were measured in mouse serum and AML12 cell culture supernatants using ELISA kits according to the manufacturer’s instructions. RNA Extraction and Quantitative Real-time PCR (qRT-PCR) Total RNA was isolated from tissues or cultured cells using TRIzol reagent (YEASEN, 19202ES60). Reverse transcription was performed using the Hifair® II 1st Strand cDNA Synthesis SuperMix for qRT-PCR (YEASEN, 11123ES60). Quantitative PCR was conducted using the Hieff® qRT-PCR SYBR Green Master Mix (YEASEN, 11200ES50) on an ABI 7500 Real-Time PCR system (Thermo Fisher Scientific, USA). The amplification protocol consisted of 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s, 60 °C for 20 s, and 72 °C for 31 s. GAPDH was used as the internal reference gene. Relative gene expression levels were calculated using the 2⁻ΔΔCt method. Primer sequences are listed in Table 1. Table 1Primer Sequences Used for qRT-PCR.Gene NamePrimers (5’-3’)Homo-IL-1β-FATGATGGCTTATTACAGTGGCAAHomo-IL-1β-RGTCGGAGATTCGTAGCTGGAHomo-IL-6-FTGAACCCCAGACCAGACTGAHomo-IL-6-RCCTTCACAGAGAGGGTCACAGHomo-TNF-α-FCCTCTTCTCATTCCTGCTTGTGGHomo-TNF-α-RGGCCATTTGGGAACTTCTCATCHomo-SLC7A11-FCACTTTTTGCCCTGGAGCTACTHomo-SLC7A11-RGAAAATCTGGATCCGGGCACTHomo-GPX4-FCAAAGTCCTAGGAAACGCCCHomo-GPX4-RGCTGTTGCAGTACTGGGGAGHomo-STAT1-FGCCTCTCATTGTCACCGAAGAACHomo-STAT1-RTGGCTGACGTTGGAGATCACCAHomo-GAPDH-FCTGGGCTACACTGAGCACCHomo-GAPDH-RAAGTGGTCGTTGAGGGCAATG Primer Sequences Used for qRT-PCR. Western Blot Analysis Tissues and cells were lysed in RIPA buffer (G2002, Servicebio, China) supplemented with 1 mM PMSF (ST506, Beyotime, China). Lysates were centrifuged at 12,000×g for 5 min, and protein concentrations were determined using a BCA Protein Assay Kit (P0012, Beyotime, China). Equal amounts of protein were mixed with 5× loading buffer (P0015L, Beyotime, China) and boiled for 10 min. Proteins were separated by SDS–PAGE and transferred onto PVDF membranes. After blocking, membranes were incubated overnight at 4 °C with primary antibodies, followed by incubation with HRP-conjugated secondary antibodies for 2 h at room temperature. Protein bands were visualized using a chemiluminescent substrate (MA0186, Meilunbio, China). Primary antibodies included IL-1β (1:10000, 16806-1-AP, Proteintech, China), IL-18 (1:50000, 10663-1-AP, Proteintech, China), CD63 (1:2000, AB-3713000, Abmart, China), CD9 (1:2000, M050808S, Abmart, China), TSG101 (1:2000, T55985XS, Abmart, China), SLC7A11 (1:4000, 26864-1-AP, Proteintech, China), GPX4 (1:4000, 67763-1-Ig, Proteintech, China), ACSL4 (1:50000, 22401-1-AP, Proteintech, China), Nrf2 (1:2000, 16396-1-AP, Proteintech, China), LC3 (1:8000, 14600-1-AP, Proteintech, China), and p62 (1:50000, 18420-1-AP, Proteintech, China) . Exosome Isolation and Characterization Serum samples were collected from LPS-treated mice in EDTA-containing tubes and processed within 2 h. Samples were centrifuged at 3,000×g for 10 min at 4 °C, and the supernatant was diluted with seven volumes of PBS. The diluted samples were filtered through 0.22 μm membranes and ultracentrifuged at 200,000×g for 2 h at 4 °C. The resulting pellets were resuspended in PBS and ultracentrifuged again at 200,000×g for 1 h. Purified exosomes were finally resuspended in PBS and stored at 4 °C. Exosome morphology and size distribution were characterized using transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). Expression of exosome marker proteins (CD63, CD9, and TSG101) was confirmed by Western blot analysis. STAT1 Inhibition and Overexpression To inhibit STAT1 expression, AML12 cells were pretreated with fludarabine (50 µM; CM00136, Proteintech, China) for 1 h before exposure to exosomes. For STAT1 overexpression, AML12 cells were infected with a lentiviral vector (GL180, pcSLenti-EF1-EGFP-P2A-Puro-CMV-Stat1-3×FLAG-WPRE; H36963, GeneChem, China). Seventy-two hours after infection, overexpression efficiency was confirmed by Western blot analysis. Autophagy Inhibition and Activation In the in vitro experiments, autophagy was inhibited by pre-treating AML12 cells with chloroquine (CQ; 10 µmol/L; C6628, Sigma-Aldrich, USA) for 1 h prior to exosome exposure. To activate autophagy, AML12 cells were pretreated with rapamycin (20 nmol/L; 553210, Sigma-Aldrich, USA) for 1 h before exosome treatment. In the in vivo experiments, autophagy inhibition was achieved by intraperitoneal injection of CQ (60 mg/kg) administered 1 h before exosome injection. For autophagy activation, rapamycin (1 mg/kg) was administered intraperitoneally 1 h prior to exosome injection. In Vivo and In Vitro Exosome Treatments For in vivo experiments, serum-derived exosomes from the corresponding groups were administered via tail vein injection at a dose of 300 µg per mouse. Twenty-four hours after injection, mice were euthanized, and liver tissues were harvested for subsequent analyses. For in vitro experiments, AML12 cells were pretreated with GW4869 (20 µmol/L) for 1 h to minimize the interference of endogenous exosome secretion. GW4869 is a neutral sphingomyelinase inhibitor that suppresses exosome biogenesis and release. After pretreatment, AML12 cells were co-cultured with serum-derived exosomes at a concentration of 100 µg/mL at 37 °C for 24 h. After incubation, cells and culture supernatants were collected for subsequent analyses. Immunofluorescence Staining Cells and liver tissues were fixed with 4% paraformaldehyde (P0099-3 L, Beyotime, China), permeabilized with 0.1% Triton X-100, and blocked with 10% bovine serum albumin (BSA; A8010, Solarbio, China). Samples were incubated overnight at 4 °C with primary antibodies against GPX4 (1:200, 67763-1-IG, Proteintech, China) or LC3 (1:200, 81004-1-RR, Proteintech, China), followed by incubation with Alexa Fluor-conjugated secondary antibodies (1:500, F2761, Thermo Fisher Scientific, China) for 1 h at room temperature. Nuclei were counterstained with DAPI (C0065, Solarbio, China) for 10 min, and fluorescence images were captured using a fluorescence microscope. Detection of Reactive Oxygen Species (ROS) Frozen liver sections were incubated with ROS detection reagent (G1045, Servicebio, China) in a humidified chamber at 37 °C for 30 min in the dark. After washing with PBS three times, the sections were stained with DAPI (G1012, Servicebio, China), and mounted using antifade mounting medium (G1401, Servicebio, China). Fluorescence images were obtained using a Nikon ECLIPSE C1 fluorescence microscope (Nikon, Japan). Measurement of Fe²⁺, Tissue Iron, Malondialdehyde (MDA), and GSH Intracellular Fe²⁺ levels were determined using an iron assay kit (E-BC-K881-M, Elabscience, China). Total tissue iron content was quantified using a tissue iron detection kit (AKIC001C, Boxbio, China). Lipid peroxidation, a hallmark of ferroptosis, was assessed by measuring MDA levels (AKFA013M, Boxbio, China).The antioxidant capacity was evaluated by measuring GSH levels (AKPR008M, Boxbio, China), following the manufacturer’s instructions. RNA Sequencing and Analysis After 24 h co-culture of AML12 cells with serum-derived exosomes from LPS-treated or untreated mice, total RNA was extracted using TRIzol reagent (YEASEN, 19202ES60). RNA purity and concentration were determined using a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA), and RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA). cDNA libraries were prepared using the VAHTS Universal V10 total RNA was extracted for transcriptome sequencing (RNA-seq) Library Prep Kit (Premixed Version), and sequencing was performed by OE Biotech Co., Ltd. (Shanghai, China). RNA Interference of STAT1 Adeno-associated virus serotype 8 (AAV8) vectors carrying STAT1 shRNA or scrambled control shRNA were synthesized by GeneChem (Shanghai, China). The targeting sequences were: STAT1-shRNA#1, 5′-GGAGGTCTTTGTTCCCTTTCA-3′; STAT1-shRNA#1, 5′-GGAGGTCTTTGTTCCCTTTCA-3′; STAT1-shRNA#2, 5′-GGTCTTTGTTCCCTTTCAGAC-3′; STAT1-shRNA#2, 5′-GGTCTTTGTTCCCTTTCAGAC-3′; Scrambled control, 5′-GGTGTATGGGCTACTATAGAA-3′. Scrambled control, 5′-GGTGTATGGGCTACTATAGAA-3′. AAV8 vectors were injected via the tail vein four weeks before serum exosome administration. Statistical Analysis All data are presented as mean ± standard deviation (SD). Comparisons between two groups were performed using Student’s t-test, while one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used for multiple-group comparisons. A P value < 0.05 was considered statistically significant. All statistical analyses were conducted using GraphPad Prism software (version 9.0). Results Elevated Levels of Circulating Exosomes in Patients with SALI Positively Correlate with Serum AST and ALT To verify the clinical relevance of our subsequent experiments, a preliminary analysis was conducted using plasma samples collected from patients. The expression levels of the exosome-specific markers CD63, CD9, and TSG101 in human plasma were measured by ELISA. Previous studies have demonstrated that CD63 and CD9, members of the tetraspanin protein family that are highly enriched on exosomal membranes, serve as reliable markers for exosomes, with CD63 exhibiting stable accumulation along the endocytic pathway [18, 19]. Notably, Yunjoo Im et al. reported that elevated CD63 levels are associated with the severity of organ failure in patients with sepsis and may serve as a predictor of mortality [20]. In addition, other proteins such as Alix and TSG101 are involved in exosome biogenesis and membrane trafficking [21]. Based on these findings, we evaluated serum exosome abundance by quantifying the expression of CD63, CD9, and TSG101. The results revealed that plasma levels of these exosomal markers were significantly higher in patients with sepsis-associated liver injury (SALI, n = 40) than in septic patients without liver injury (n = 40) and healthy controls (n = 20) (Figs. 1A–C). Increased circulating exosome levels in patients with SALI are positively correlated with serum AST and ALT levels. (A–C) Plasma concentrations of exosomal markers CD63 (A), CD9 (B), and TSG101 (C) were measured using ELISA in healthy controls, septic patients without liver injury, and patients with SALI. (D–F) Correlation analyses of exosomal markers CD63 (D), CD9 (E), and TSG101 (F) with serum levels of AST in patients with SALI. (G–I) Correlation analyses of exosomal markers CD63 (G), CD9 (H), and TSG101 (I) with serum levels of ALT in patients with SALI. (J–L) Correlation analyses of exosomal markers CD63 (J), CD9 (K), and TSG101 (L) with serum levels of LDH in patients with SALI. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 Further correlation analyses demonstrated that the plasma concentrations of the exosomal markers CD63, CD9, and TSG101 were positively correlated with the serum levels of AST and ALT in patients with liver injury (Figs. 1D–I). To further exclude the possibility that the elevated levels of exosomal markers were attributable to cell necrosis or nonspecific cell lysis, LDH levels were obtained from routine laboratory test results and their correlations with plasma concentrations of CD63, CD9, and TSG101 were analyzed in patients with liver injury. The results showed no significant correlations between LDH levels and these exosomal markers (Figs. 1J–L), suggesting that the observed increase in exosomal markers was unlikely to result from cell necrosis or nonspecific cellular disruption. Taken together, these findings indicate that circulating exosomes are markedly increased in patients with SALI and may reflect the extent of hepatic injury during sepsis. These findings indicate that the expression levels of exosomal marker proteins were markedly increased in patients with SALI and positively correlated with the severity of hepatic dysfunction. This observation suggests that exosomes may play an important role in the pathogenesis of SALI. Accordingly, we next aimed to elucidate the relationship between exosomes and SALI. Establishment of a Mouse Model of SALI To investigate the role of serum exosomes in SALI, serum-derived exosomes were isolated from mice with LPS-induced SALI and subsequently administered to healthy mice and normal hepatocytes to assess their pathogenic potential. Initially, a murine model of SALI was established by intraperitoneal injection of LPS (n = 6). To validate the effectiveness of the model, the serum levels of the proinflammatory cytokines IL-1β (Fig. 2A) and IL-18 (Fig. 2B) were measured using ELISA. Both cytokines were significantly elevated in the LPS-treated group compared with the control group. In addition, the serum levels of hepatic injury markers AST (Fig. 2C) and ALT (Fig. 2D) were markedly increased in the LPS group. Consistent with these findings, qRT-PCR and Western blot analyses demonstrated upregulated expression of IL-1β (Fig. 2E and G), IL-6 (Fig. 2F), and IL-18 (Fig. 2G) at both the mRNA and protein levels in liver tissues. Histopathological examination further revealed severe hepatic injury in LPS-treated mice, characterized by marked inflammatory cell infiltration, tissue edema, and hemorrhagic lesions (Fig. 2H). Establishment of a mouse model of SALI. Mice were intraperitoneally injected with LPS, and serum and liver tissues were collected 24 h later. (A–B) Serum concentrations of the inflammatory cytokines IL-1β (A) and IL-18 (B) were measured by ELISA. (C–D) Serum levels of hepatic injury markers AST (C) and ALT (D) were determined using commercial assay kits. (E–F) Hepatic mRNA expression of IL-1β (E) and IL-6 (F) was quantified by qRT-PCR. (G) Protein expression levels of IL-1β and IL-6 in liver tissues were analyzed by Western blot. (H) Representative H&E staining of liver sections showing inflammatory infiltration and tissue injury. Scale bar = 50 μm. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 Collectively, these results confirm the successful establishment of an LPS-induced SALI model, providing a reliable experimental foundation for subsequent investigations into the pathogenic role of serum exosomes. Isolation and Characterization of Peripheral Circulating Exosomes To investigate the role of peripheral circulating exosomes in SALI, serum-derived exosomes were isolated from LPS-induced septic mice and control mice. TEM revealed that the isolated vesicles displayed the typical cup-shaped morphology characteristic of exosomes, with diameters ranging from approximately 40–150 nm (Fig. 3A). NTA demonstrated that the particle size distribution peaked within the 40–150 nm range, which is consistent with previously reported exosome profiles (Fig. 3B) [22]. Notably, NTA quantification showed a significantly higher concentration of circulating exosomes in the LPS-treated group than in the control group (Fig. 3C), suggesting that systemic inflammation promotes exosome release. Western blot analysis further confirmed the expression of the exosomal marker proteins CD9, CD63, and TSG101 in both groups (Fig. 3D), thereby validating the successful isolation and identity of exosomes. Moreover, the expression levels of these markers were markedly increased in the LPS-treated group compared with the control group (Fig. 3D), indicating that the development of SALI may be associated with increased exosome activity. Isolation and characterization of peripheral circulating exosomes. (A) TEM images of serum-derived exosomes isolated from LPS-induced septic mice and control mice. Scale bar = 200 nm. (B) NTA of isolated exosomes from septic mice–derived exosomes (sep-Exo) and control mice–derived exosomes (con-Exo), showing the particle size distribution profile. (C) NTA quantification of serum exosome concentrations in control and LPS-treated mice (n = 6). (D) Western blot analysis of exosomal marker proteins CD9, CD63, and TSG101 in the isolated exosomes Peripheral Circulating Exosomes Induce AML12 Cell Injury Through Ferroptosis and Autophagy Exosomes were successfully isolated from mice and co‑incubated with AML12 cells for 24 h (Fig. 4A). After 24 h of incubation, the levels of hepatocellular injury markers AST and ALT were markedly elevated in AML12 cells treated with sep-Exo, whereas both parameters were significantly reduced in the con-Exo and GW4869-pretreated groups (Fig. 4B). To further evaluate the contribution of exosomes to SALI, the expression of proinflammatory cytokines was assessed by ELISA, qRT-PCR, and Western blot. The results showed that IL-1β (Figs. 4C, H, E), IL-18 (Figs. 4D, H), IL-6 (Fig. 4F), and TNF-α (Fig. 4G) were significantly upregulated in the sep-Exo–treated group, whereas GW4869 pretreatment markedly attenuated these increases. These findings suggest that peripheral circulating exosomes contribute to the progression of SALI. Peripheral circulating exosomes induce AML12 cell injury through ferroptosis and autophagy. (A) Schematic illustration of the experimental design. (B) Levels of hepatocellular injury markers AST and ALT in AML12 cells were measured using commercial assay kits. (C–D) Concentrations of inflammatory cytokines IL-1β (C) and IL-18 (D) in the culture supernatant were determined by ELISA. (E–G) mRNA expression levels of IL-1β (E), IL-6 (F), and TNF-α (G) in AML12 cells were analyzed by qRT-PCR. (H) Protein expression levels of IL-1β and IL-18 in AML12 cells were evaluated by Western blot analysis. (I–K) Intracellular levels of Fe²⁺ (I), MDA (J), and GSH (K) were determined using corresponding assay kits. (L–M) qRT-PCR analysis of the mRNA expression of SLC7A11 (L) and GPX4 (M) in AML12 cells. (N) Immunofluorescence staining showing intracellular ROS levels in AML12 cells under different treatments (Blue: DAPI; Red: ROS). (O) Western blot analysis of SLC7A11, GPX4, ACSL4, and Nrf2 protein expression in AML12 cells. (P) Immunofluorescence staining of LC3 in AML12 cells under different treatments (Blue: DAPI; Red: LC3). (Q) Western blot analysis of LC3 and p62 protein expression in AML12 cells. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 Previous studies have demonstrated that excessive levels of labile iron are hepatotoxic, triggering ferroptosis and exacerbating liver injury under LPS challenge. Increasing evidence indicates a close association between ferroptosis and sepsis [9]. Moreover, accumulating studies suggest a functional interplay between autophagy and ferroptosis, in which autophagy regulates iron-dependent lipid peroxidation and ROS accumulation [23, 24]. To further elucidate the mechanisms underlying exosome-mediated hepatocellular injury, we systematically assessed markers associated with ferroptosis and autophagy. Compared with the con-Exo group, sep-Exo treatment significantly increased intracellular Fe²⁺ (Fig. 4I) and MDA (Fig. 4J) levels, while reducing GSH levels (Fig. 4K). These alterations were partially reversed by GW4869 pretreatment, as Fe²⁺ and MDA levels decreased while GSH levels were restored. At the transcriptional level, qRT-PCR revealed that the mRNA expression of SLC7A11 (Fig. 4L) and GPX4 (Fig. 4M) was markedly downregulated in sep-Exo-treated cells, whereas GW4869 pretreatment restored their expression. Consistently, Western blot analysis demonstrated reduced protein levels of SLC7A11, GPX4, and nuclear factor erythroid 2–related factor 2 (Nrf2), accompanied by increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4) in the sep-Exo group; GW4869 treatment partially restored these protein levels (Fig. 4O). The SLC7A11–GSH–GPX4 axis is a classical ferroptosis-suppressing pathway [25, 26]. Within this pathway, SLC7A11 mediates cystine uptake, promoting cysteine and GSH synthesis, whereas GPX4 utilizes GSH as a cofactor to reduce lipid peroxides, thereby inhibiting ferroptosis [25, 27]. The concurrent downregulation of SLC7A11, GSH, and GPX4 observed in our study suggests that sep-Exo may promote ferroptosis by disrupting this protective axis. Furthermore, immunofluorescence analysis revealed that sep-Exo markedly increased intracellular ROS accumulation, which was significantly attenuated by GW4869 pretreatment (Fig. 4N). Regarding autophagy-related markers, sep-Exo treatment increased LC3 expression while reducing p62 levels, whereas GW4869 pretreatment reversed these alterations (Fig. 4P and Q). Collectively, these findings indicate that septic serum-derived exosomes (sep-Exo) induce AML12 hepatocellular injury by promoting both ferroptosis and autophagy, likely through modulation of the SLC7A11–GSH–GPX4 signaling axis. STAT1 is Identified as a Key Differentially Expressed Gene Mediating the Effects of Septic Exosomes and a Potential Upstream Regulator of SLC7A11 To further elucidate the molecular mechanisms by which septic serum-derived exosomes promote autophagy-and ferroptosis-associated hepatocellular injury, equal amounts of serum exosomes derived from PBS-treated control mice (con-Exo) and LPS-treated septic mice (sep-Exo) were applied to AML12 cells. After 24 h of treatment, total RNA was extracted for transcriptome sequencing (RNA-seq). RNA-seq analysis revealed substantial transcriptional differences between the two groups (Fig. 5A). Principal component analysis (PCA) and sample correlation heatmaps analysis demonstrated high intragroup reproducibility and clear intergroup separation (Figs. 5B–C), confirming that exposure to different exosomal sources induced distinct global gene expression profiles in AML12 cells. Differential expression analysis identified a total of 1,556 upregulated genes and 1,238 downregulated genes (|log₂FC| > 1, p < 0.05) in the sep-Exo group compared with the con-Exo group. Among the upregulated genes, STAT1 exhibited one of the most pronounced increases in expression (Figs. 5D–E), suggesting that it may serve as a key transcriptional mediator of the cellular response to septic exosomes. STAT1 is identified as a key differentially expressed gene mediating the effects of septic exosomes and a potential upstream regulator of SLC7A11. (A) Distribution of differentially expressed genes (DEGs) between the control exosome (con-Exo, n = 3) and septic exosome (sep-Exo, n = 3) groups. (B) Heatmap showing pairwise correlation coefficients among all samples. (C) Boxplot of fragments per kilobase of transcript per million mapped reads (FPKM) values, indicating high within-group consistency and clear between-group variation. (D) Volcano plot illustrating DEGs between the two groups. Gray dots represent non-significant genes, whereas red and blue dots indicate significantly upregulated and downregulated genes, respectively. (E) Heatmap of significantly differentially expressed genes in AML12 cells treated with con-Exo or sep-Exo. (F) Predicted upstream transcription factors regulating SLC7A11, identified using the PROMO database. (G) Venn diagram showing the overlap between upregulated genes in the sep-Exo group and predicted transcription factors binding to the SLC7A11 promoter region, highlighting STAT1 as the only overlapping candidate gene To explore the potential role of STAT1 in regulating ferroptosis, we retrieved the promoter sequence of the mouse SLC7A11 gene (− 2000 nt upstream to + 100 nt downstream of the transcription start site) from the UCSC Genome Browser and predicted transcription factor binding site (TFBS) using the PROMO database (species: Mus musculus, dissimilarity threshold: 5%). A total of 29 potential transcription factors were predicted to bind within this promoter region. By integrating these TFBS predictions with our RNA-seq differential expression data, STAT1 was identified as a putative upstream regulator of SLC7A11 (Fig. 5F). Furthermore, cross-comparison analysis revealed that STAT1 was the only overlapping gene between the 1,556 upregulated genes in the sep-Exo group and the 29 predicted SLC7A11-binding transcription factors (Fig. 5G). These findings strongly suggest that STAT1 may function as a direct upstream regulatory factor of SLC7A11, mediating the pro-ferroptotic effects of septic exosomes during SALI. Peripheral Circulating Exosomes Regulate SALI through STAT1-mediated Modulation of Ferroptosis and Autophagy To elucidate the regulatory role of STAT1 in exosome-mediated ferroptosis and autophagy during SALI, AML12 cell models with altered STAT1 expression were established. A stable STAT1-overexpressing (OE-STAT1) cell line was generated via lentiviral transduction, whereas STAT1 inhibition was achieved by treating cells with Fludarabine (FLUD, 50 µM). Western blot analysis confirmed a significant downregulation of STAT1 in the FLUD-treated group and marked upregulation in the OE-STAT1 group, indicating successful establishment of the STAT1-modulated models (Fig. 6B). Peripheral circulating exosomes regulate SALI through STAT1-mediated modulation of ferroptosis and autophagy. (A) Schematic illustration of the experimental design. (B) Western blot analysis of STAT1 protein expression in AML12 cells, AML12 cells treated with the STAT1 inhibitor Fludarabine (FLUD, 50 µM), and STAT1-overexpressing AML12 cells (OE-STAT1). (C–D) AST and ALT levels were measured in AML12 cells using commercially available assay kits. (E–F) ELISA quantification of IL-1β and IL-18 secretion in cell culture supernatants. (G–I) qRT-PCR analysis of IL-1β, IL-6, and TNF-α mRNA expression in AML12 cells. (J) Western blot analysis of IL-1β and IL-18 protein expression. (K–M) Intracellular Fe²⁺, MDA, and GSH levels were determined using biochemical assay kits. (N–O) qRT-PCR analysis of SLC7A11 and GPX4 mRNA expression. (P) Immunofluorescence staining of intracellular ROS in AML12 cells under different treatments. Blue: DAPI; Red: ROS. (Q) Western blot analysis of SLC7A11, GPX4, ACSL4, and Nrf2 protein expression. (R) Immunofluorescence staining of LC3 in AML12 cells under different treatments. Blue: DAPI; Red: LC3. (S) Western blot analysis of LC3 and p62 protein expression in AML12 cells. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 Equal amounts of serum exosomes derived from PBS-treated (con-Exo) or LPS-treated (sep-Exo) mice were applied to AML12 cells for 24 h. In parallel, sep-Exo was co-incubated with STAT1-inhibited or STAT1-overexpressing AML12 cells for 24 h (Fig. 6A). Treatment with sep-Exo significantly increased hepatocellular injury markers AST and ALT, whereas STAT1 inhibition reversed this effect. Conversely, STAT1 overexpression further exacerbated the elevation of AST and ALT levels (Figs. 6C–D). To further verify the role of STAT1 in exosome-induced inflammatory injury, the expression of pro-inflammatory cytokines IL-1β (Figs. 6E, G, J), IL-18 (Figs. 6F, J), IL-6 (Fig. 6H), and TNF-α (Fig. 6I) were assessed by ELISA, qRT-PCR, and Western blot. STAT1 inhibition markedly reduced cytokine expression, whereas STAT1 overexpression enhanced it, indicating that STAT1 is a pivotal mediator of exosome-induced inflammatory responses and hepatocellular injury. Given that ferroptosis and autophagy are key mechanisms of septic exosome–induced hepatocellular injury and that transcriptomic analysis suggested STAT1 as an upstream regulator of SLC7A11, we next investigated whether STAT1 modulates ferroptosis via the SLC7A11–GSH–GPX4 axis, a canonical ferroptosis-suppressing pathway [25, 26]. STAT1 suppression significantly decreased intracellular Fe²⁺ and MDA levels while increasing GSH content, whereas STAT1 overexpression produced opposite effects (Figs. 6K–M). Consistently, qRT-PCR revealed that STAT1 inhibition upregulated SLC7A11 and GPX4 mRNA, whereas STAT1 overexpression repressed their transcription (Figs. 6N–O), indicating that STAT1 negatively regulates the SLC7A11–GSH–GPX4 pathway. At the protein level, Western blot analysis confirmed that STAT1 inhibition enhanced SLC7A11, GPX4, and Nrf2 expression while reducing ACSL4, whereas STAT1 overexpression reversed these changes (Fig. 6Q). Immunofluorescence staining showed that STAT1 inhibition markedly attenuated ROS accumulation, whereas STAT1 overexpression promoted excessive ROS generation (Fig. 6P). Regarding autophagy, both immunofluorescence and Western blot analyses demonstrated that STAT1 inhibition decreased the LC3/GAPDH ratio and increased p62 accumulation, whereas STAT1 overexpression promoted LC3 expression and reduced p62 levels (Figs. 6R–S). Collectively, these results indicate that peripheral circulating exosomes upregulate STAT1, which in turn activates autophagy and suppresses the SLC7A11–GSH–GPX4 axis, thereby promoting ferroptosis and contributing to SALI. Peripheral Circulating Exosomes Aggravate SALI by Promoting Autophagy-dependent Ferroptosis Based on our previous findings, peripheral circulating exosomes exacerbate SALI through STAT1-mediated regulation of autophagy and ferroptosis. However, the mechanistic relationship between autophagy and ferroptosis remains to be further clarified. Therefore, AML12 cells were pretreated with the autophagy inhibitor CQ or the autophagy activator rapamycin for 1 h, followed by incubation with sep-Exo for 24 h prior to subsequent analyses (Fig. 7A). Peripheral circulating exosomes aggravate SALI by promoting autophagy-dependent ferroptosis. (A) Schematic illustration of the experimental design. (B-C) AST and ALT levels were measured in AML12 cells using commercially available assay kits. (D-E) ELISA analysis of IL-1β and IL-18 secretion in cell supernatants. (F-H) qRT-PCR analysis of IL-1β, IL-6, and TNF-α mRNA expression in AML12 cells. (I) Western blot analysis of SLC7A11 and GPX4 protein expression. (J-K) Intracellular Fe²⁺ and MDA levels were determined using biochemical assay kits. (L) Western blot analysis of LC3 and p62 protein expression in AML12 cells. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 Biochemical analyses revealed that sep-Exo treatment significantly increased AST and ALT levels compared with the control group. Autophagy inhibition markedly reduced these elevations, whereas autophagy activation further exacerbated them (Figs. 7B, C). To further elucidate the role of autophagy in exosome-induced hepatic injury, inflammatory cytokines (IL-1β, IL-18, IL-6, and TNF-α) in cell supernatants were quantitatively assessed by ELISA and qRT-PCR. The results demonstrated that sep-Exo treatment significantly upregulated these inflammatory mediators, This effect was markedly reversed by autophagy inhibition, whereas autophagy activation further intensified the inflammatory response (Figs. 7D–H). To investigate the link between autophagy and ferroptosis, we examined the canonical ferroptosis-related SLC7A11–GPX4 signaling pathway. Western blot analysis showed that inhibition of autophagy suppressed ferroptosis and alleviated hepatic injury, whereas activation of autophagy promoted ferroptosis and aggravated liver injury (Fig. 7I). Consistently, compared with the con-Exo group, hepatic Fe²⁺ and MDA levels were significantly elevated in the sep-Exo group. Autophagy inhibition markedly decreased Fe²⁺ and MDA levels, whereas autophagy activation further increased their accumulation (Figs. 7J, K). In addition, analysis of autophagy-related proteins LC3 and p62 revealed that sep-Exo treatment markedly activated autophagy. CQ treatment effectively suppressed autophagy, whereas rapamycin treatment significantly enhanced autophagic activity (Fig. 7L). Collectively, these findings indicate that peripheral circulating exosomes aggravate SALI by promoting autophagy-dependent ferroptosis. Peripheral Circulating Exosomes Mediate SALI through STAT1-Dependent Regulation of Ferroptosis and Autophagy To validate the reliability of the above in vitro findings, we further conducted in vivo experiments in C57BL/6 mice. A liver-specific STAT1 knockdown mouse model (sh-STAT1) was established via shRNA lentiviral transfection. qRT-PCR analysis confirmed that among three shRNA constructs, shRNA#1 exhibited the highest silencing efficiency and was therefore selected for subsequent in vivo experiments (Fig. 8B). Western blot analysis further verified a marked reduction in hepatic STAT1 protein expression in sh-STAT1 mice (Fig. 8C). Subsequently, equal amounts of serum-derived exosomes from PBS-treated (con-Exo) or LPS-treated (sep-Exo) mice were intravenously injected via the tail vein (Fig. 8A). After 24 h, mouse plasma and liver tissues were collected for analysis. Peripheral circulating exosomes regulate SALI through STAT1-mediated modulation of ferroptosis and autophagy. (A) Schematic illustration of the in vivo experimental design. (B) qRT-PCR analysis of STAT1 knockdown efficiency using different shRNA constructs. (C) Western blot analysis of STAT1 protein expression in C57BL/6 mice with hepatic STAT1 suppression induced by shRNA lentiviral transfection. (D–E) Representative H&E staining of liver sections showing histopathological changes and inflammatory cell infiltration in each group. Scale bar = 50 μm. (F–G) Serum AST and ALT levels were measured using commercially available assay kits. (H–I) ELISA quantification of inflammatory cytokines IL-1β and IL-18 in mouse serum. (J–L) qRT-PCR analysis of hepatic IL-1β, IL-6, and TNF-α mRNA expression. (M) Western blot analysis of IL-1β and IL-18 protein expression in liver tissues. (N–P) Hepatic Fe²⁺, MDA, and GSH levels were determined using biochemical assays. (Q–R) qRT-PCR analysis of SLC7A11 and GPX4 mRNA expression in liver tissues. (S) Immunofluorescence staining of hepatic ROS in mice under different treatments. Blue: DAPI; Red: ROS. (T) Western blot analysis of SLC7A11, GPX4, ACSL4, and Nrf2 protein expression in liver tissues. (U) Immunofluorescence staining of hepatic GPX4. Blue: DAPI; Green: GPX4. (V) Immunofluorescence staining of hepatic LC3. Blue: DAPI; Red: LC3. (W) Western blot analysis of LC3 and p62 protein expression in liver tissues. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 H&E staining revealed that sep-Exo–treated mice exhibited pronounced inflammatory cell infiltration, hepatocellular swelling, and hemorrhagic lesions, whereas these pathological alterations were markedly alleviated by GW4869 pretreatment or STAT1 knockdown (sh-STAT1) (Figs. 8D-E). Biochemical analyses showed that AST and ALT levels were significantly elevated in the sep-Exo group compared with controls, whereas both GW4869 treatment and STAT1 knockdown effectively reduced these liver injury markers (Figs. 8F–G). To further clarify the role of STAT1 in hepatic inflammation, we quantified the levels of inflammatory cytokines IL-1β, IL-18, IL-6, and TNF-α in liver tissues using ELISA, qRT-PCR, and Western blot analyses. The results revealed that sep-Exo treatment markedly upregulated these cytokines, whereas both GW4869 treatment and STAT1 knockdown significantly reversed this effect (Figs. 8H–M). Collectively, these findings suggest that peripheral circulating exosomes are critical mediators of SALI, with STAT1 acting as a pivotal pathogenic regulator. To elucidate the mechanistic basis of ferroptosis and autophagy regulation in this process, we next assessed the impact of circulating exosomes and STAT1 modulation on key ferroptosis-related parameters. Compared with the con-Exo group, hepatic Fe²⁺ and MDA levels were significantly elevated, whereas GSH content was reduced in the sep-Exo group. Both GW4869 treatment and STAT1 knockdown effectively reversed these changes (Figs. 8N–P). qRT-PCR analysis revealed that sep-Exo markedly downregulated SLC7A11 and GPX4 mRNA expression, whereas both GW4869 treatment and STAT1 knockdown restored their expression (Figs. 8Q–R), indicating that STAT1 participates in regulating the SLC7A11–GSH–GPX4 axis. Consistently, Western blot results confirmed that sep-Exo decreased SLC7A11, GPX4, and Nrf2 expression while increasing ACSL4 levels; these alterations were reversed by either GW4869 treatment or STAT1 knockdown (Fig. 8T). Immunofluorescence staining of GPX4 showed a similar pattern (Fig. 8U). In addition, ROS accumulation was markedly enhanced in sep-Exo–treated mice but was significantly reduced following GW4869 treatment or STAT1 knockdown (Fig. 8S). With respect to autophagy, immunofluorescence and Western blot analyses revealed that sep-Exo treatment promoted LC3/GAPDH expression and decreased p62 accumulation, indicating enhanced autophagic activity. Conversely, both GW4869 treatment and STAT1 knockdown attenuated autophagy, as evidenced by decreased LC3/GAPDH and increased p62 expression (Figs. 8V–W). Taken together, these in vivo results demonstrate that peripheral circulating exosomes exacerbate SALI through STAT1 activation, which simultaneously enhances autophagy and suppresses the SLC7A11–GPX4 pathway, thereby promoting ROS accumulation and ferroptosis. These findings provide compelling evidence that STAT1 serves as a central regulator linking exosome-mediated signaling with ferroptosis–autophagy crosstalk during the pathogenesis of SALI. Notably, the shRNA viral vector alone did not alleviate liver injury induced by peripheral circulating exosomes, as no improvement was observed in the sep + Vehicle or sep + sh-Scr groups (Fig. 8D-W). In contrast, STAT1 knockdown markedly attenuated exosome-mediated hepatic injury, indicating that the protective effect was specifically attributable to STAT1 modulation rather than nonspecific effects of viral transduction. Peripheral Circulating Exosomes Exacerbate SALI by Promoting Autophagy-dependent Ferroptosis In Vivo Based on the aforementioned findings, we demonstrated that peripheral circulating exosomes promote SALI through STAT1-mediated regulation of autophagy and ferroptosis. However, the intrinsic relationship between autophagy and ferroptosis remains to be validencapsulated within aated in vivo. To this end, C57BL/6 mice were pretreated with the autophagy inhibitor CQ or the autophagy activator rapamycin via intraperitoneal injection 1 h prior to tail vein administration of sep-Exo. Mice were euthanized 24 h later for subsequent analyses (Fig. 9A). Peripheral circulating exosomes exacerbate SALI by promoting autophagy-dependent ferroptosis in vivo. (A) Schematic illustration of the experimental design. (B-C) Serum AST and ALT levels were measured using commercially available assay kits. (D-E) ELISA quantification of inflammatory cytokines IL-1β and IL-18 in mouse serum. (F-H) qRT-PCR analysis of hepatic IL-1β, IL-6, and TNF-α mRNA expression. (I) Western blot analysis of SLC7A11 and GPX4 protein expression in liver tissues. (J-K) Hepatic Fe²⁺ and MDA levels were determined using biochemical assays. (L) Western blot analysis of LC3 and p62 protein expression in liver tissues. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 Biochemical analyses revealed that sep-Exo treatment significantly increased serum AST and ALT levels compared with controls. Autophagy inhibition markedly attenuated these elevations, whereas autophagy activation further exacerbated them (Figs. 9B-C). To further clarify the role of autophagy in exosome-mediated liver injury, levels of inflammatory cytokines (IL-1β, IL-18, IL-6, and TNF-α) in liver tissues were quantified using ELISA and qRT-PCR. The results showed that sep-Exo treatment significantly upregulated these inflammatory mediators. This effect was markedly reversed by autophagy inhibition, whereas autophagy activation further intensified the inflammatory response (Figs. 9D–H). The relationship between autophagy and ferroptosis was further examined by assessing alterations in the canonical ferroptosis-related SLC7A11–GPX4 signaling pathway. Western blot analysis demonstrated that autophagy inhibition significantly suppressed ferroptosis and alleviated liver injury, whereas autophagy activation promoted ferroptosis and aggravated hepatic injury (Fig. 9I). Consistently, compared with the con-Exo group, hepatic Fe²⁺ and MDA levels were significantly elevated in the sep-Exo group. Autophagy inhibition markedly reduced Fe²⁺ and MDA levels, whereas autophagy activation further increased their accumulation (Figs. 9J, K). In addition, analysis of autophagy-related proteins LC3 and p62 demonstrated that sep-Exo treatment markedly activated hepatic autophagy. CQ treatment effectively suppressed autophagy, whereas rapamycin treatment significantly enhanced autophagic activity (Fig. 9L). Collectively, these in vivo findings indicate that peripheral circulating exosomes aggravate SALI by promoting autophagy-dependent ferroptosis, consistent with the results observed in vitro. Discussion Sepsis remains one of the most formidable challenges in clinical medicine, with its global incidence and mortality continuing to rise and frequently leading to multiple organ dysfunction. Previous studies have shown that sepsis can cause extensive damage to multiple organs, including the kidneys and lungs. For instance, in a septic mouse model, γδ T17 cells were reported to migrate from the intestine to the lungs, where they regulate IL-17A–mediated pulmonary inflammation through the CCL1–Wnt/β-catenin signaling pathway in alveolar macrophages [28]. Another study demonstrated that the histone methyltransferase EZH2 modulates apoptosis and inflammation in sepsis-induced acute kidney injury [29]. In addition to these organs, the liver is also highly susceptible to septic injury. Chuanhuning has been shown to alleviate sepsis-associated acute liver injury by inhibiting ferroptosis through modulation of the gut microbiota [30], while CD39 restricts P2 × 7 receptor–mediated inflammatory signaling and mitigates sepsis-induced hepatic damage [31]. Despite these advances, the pathophysiological mechanisms underlying SALI remain incompletely understood [32–34]. LPS, a major endotoxin derived from Gram-negative bacteria, is widely used to establish experimental models of sepsis. In the present study, we successfully established an LPS-induced mouse model of SALI and isolated serum-derived exosomes, which were subsequently characterized and validated for downstream experiments. Exosomes serve as critical mediators of intercellular communication, transferring bioactive molecules such as growth factors, signaling lipids, and genetic material encapsulated within a lipid bilayer [35]. These vesicles are secreted by multiple cell types and are present in nearly all body fluids [36–38]. Circulating exosomes, in particular, are easily accessible, circulate systemically, and maintain remarkable structural stability, thereby exerting important regulatory functions in both physiological and pathological processes [39]. For example, serum exosomes derived from diabetic mice can be internalized by aortic endothelial cells, leading to endothelial dysfunction in healthy mice [40]. Another study demonstrated that blood-borne exosomes can be internalized by dendritic cells to induce donor-specific transplant tolerance [41]. Notably, recent evidence indicates that circulating exosomal mRNA may serve as an early predictive biomarker for persistent organ failure in acute pancreatitis [42], while exosomal miR-155 promotes macrophage proliferation and inflammatory activation [13]. Collectively, these findings underscore the critical roles of circulating exosomes in inflammation-related pathologies. However, their specific contribution to SALI remains poorly understood. In this study, we provide the first evidence that circulating exosomes from septic mice (sep-Exo) can directly induce SALI. Treatment of AML12 hepatocytes with sep-Exo significantly induced inflammatory responses, as evidenced by elevated expression of pro-inflammatory cytokines and increased AST and ALT levels, indicating hepatocellular injury. Consistent with these in vitro findings, intravenous administration of sep-Exo into healthy mice reproduced similar liver inflammation and injury. Although previous studies have not directly addressed the mechanism by which serum exosomes contribute to septic liver injury, Gao et al. reported that plasma-derived exosomes carrying miR-1-3p can target SERP1 to induce endothelial dysfunction and thereby promote septic lung injury [43]. Together with our results, these observations suggest that circulating exosomes from septic mice constitute a pro-inflammatory subpopulation capable of eliciting liver inflammation. Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, is increasingly recognized as a pivotal mechanism in sepsis pathogenesis [44]. Extensive evidence indicates that ferroptosis exacerbates inflammation, and targeting ferroptosis can mitigate sepsis-induced multi-organ injury, implying that hepatocellular ferroptosis may play a central role in SALI [44, 45]. Supporting this notion, deletion of LCN2 has been shown to aggravate ferroptosis in septic liver injury by modulating PTGS2 [46], whereas Wenqingyin alleviates SALI by suppressing ferroptosis via activation of the Nrf2 signaling pathway [47]. Mechanistically, GPX4 detoxifies lipid peroxides using GSH as a reducing cofactor to counteract oxidative injury caused by iron overload. SLC7A11, a cystine/glutamate antiporter, facilitates cystine uptake for GSH synthesis, and its downregulation depletes intracellular GSH and reduces GPX4 activity. Thus, the SLC7A11–GSH–GPX4 axis constitutes the core antioxidant defense mechanism against ferroptosis [48, 49]. Previous studies have demonstrated the critical regulatory role of this pathway in ferroptosis; for instance, systemic glucose deprivation can trigger disulfide stress and ferroptosis by inhibiting this axis [50], and suppression of this pathway in vascular smooth muscle cells drives ferroptosis and vascular calcification [51]. Consistent with these findings, serum exosomes from septic mice induced hepatocyte injury, suppressed SLC7A11, GSH, and GPX4 expression, activated autophagy, and thereby promoted ferroptosis. These results suggest that septic serum exosomes may drive ferroptosis and liver injury by inducing autophagy and disrupting the SLC7A11–GSH–GPX4 axis. Autophagy is closely associated with ferroptosis. During ferroptosis, the accumulation of iron and ROS can activate autophagy, while excessive autophagic activity further increases intracellular iron and ROS, establishing a positive feedback loop that accelerates ferroptotic cell death [52]. Autophagy plays a context-dependent dual role in ferroptosis [53–55]. However, the precise function of autophagy in SALI remains largely undefined. Elucidating the crosstalk between these two processes may provide novel mechanistic insights and therapeutic targets for sepsis. Although autophagy is physiologically protective, excessive or dysregulated autophagy during sepsis is associated with aggravated inflammation and poorer outcomes. In experimental models, autophagy inhibition alleviates cytokine storm and vascular leakage, indicating a pathological role under specific conditions [56]. Importantly, extracellular vesicles have been shown to induce both autophagy and ferroptosis in sepsis-induced acute lung injury, further exacerbating inflammatory damage [57]. Collectively, these findings suggest that excessive autophagy in sepsis may contribute to organ injury, highlighting the need for precise therapeutic modulation. STAT1, a key member of the STAT family, regulates diverse biological processes, including cell proliferation, cell death, and immune responses. Recent studies have highlighted its pathogenic involvement in hepatic ischemia-reperfusion and drug-induced liver injury [58], yet its role in SALI remains unexplored. Our RNA sequencing data revealed that STAT1 was among the most significantly upregulated genes in AML12 cells treated with sep-Exo, suggesting its potential involvement in exosome-mediated hepatic injury. Functional experiments demonstrated that inhibition of STAT1 attenuated sep-Exo–induced hepatocellular injury and inflammatory cytokine production, whereas STAT1 overexpression further exacerbated these effects. These results were consistent in both in vitro and in vivo models. Previous studies have shown that esculin alleviates early sepsis by suppressing NF-κB and STAT1/3 signaling [59], and that the IFIH1/IRF1/STAT1 axis promotes sepsis-related inflammatory lung injury via driving M1 macrophage polarization [60], supporting our observation that STAT1 activation exacerbates septic inflammation. Importantly, we identified STAT1 as an upstream regulator of SLC7A11. Mechanistically, STAT1 activation suppresses SLC7A11 expression, reduces cellular antioxidant capacity, and promotes ferroptosis. Similar mechanisms have been reported in other systems, such as STAT1-mediated inhibition of SLC7A11 inducing ferroptosis in retinal pigment epithelial cells, which can be reversed by STAT1 inhibition [61]. Consistent with these findings, our data demonstrate that STAT1 inhibition restores SLC7A11–GSH–GPX4 signaling and prevents ferroptosis, whereas STAT1 overexpression intensifies ferroptotic damage [62, 63]. This study has several limitations. Although our data indicate that circulating exosomes contribute to septic liver injury, exosomes contain diverse bioactive cargos, and the specific pathogenic components responsible for this effect remain to be identified. Further studies are therefore warranted to characterize these molecules and elucidate their precise roles in the pathogenesis of SALI. From a translational perspective, our findings may offer potential therapeutic insights. Previous studies have proposed blood purification strategies aimed at selectively removing pathogenic exosomes and viral particles from the circulation, such as those developed by Aethlon Medical for cancer and hepatitis C treatment [32]. In this context, our results suggest that targeting circulating exosomes could represent a complementary therapeutic strategy for mitigating liver injury during sepsis. Notably, our study demonstrates that serum-derived exosomes are enriched in the peripheral circulation of septic mice and contribute to SALI through STAT1 upregulation. Activation of STAT1 promotes autophagy while concomitantly suppressing the SLC7A11–GSH–GPX4 axis, thereby facilitating ferroptosis. Both in vitro and in vivo, septic serum–derived exosomes were shown to exacerbate hepatocellular injury, inflammation, and oxidative stress. Collectively, these findings provide novel mechanistic insights into the role of circulating exosomes in SALI and identify STAT1-mediated autophagy–ferroptosis signaling as a potential therapeutic target. Conclusion Our study provides compelling evidence that serum-derived exosomes from LPS-induced septic mice contribute to the pathogenesis of SALI by upregulating STAT1. This activation of STAT1, in turn, induces autophagy and suppresses the SLC7A11–GSH–GPX4 axis, thereby promoting ferroptosis. Collectively, these findings advance our understanding of the molecular mechanisms underlying SALI and identify STAT1-mediated exosomal signaling as a potential therapeutic target for sepsis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary File 1 (PDF 3.94 MB) Acknowledgements The authors express their gratitude to all those who provided invaluable assistance, advice, and support for this article. Author Contributions Yu-Jia Tang, Xue Du, Bing Yin, Hui-Ying Liu, Kai Kang, Ming-Yan Zhao, Yang Gao conducted the literature search, conceived and designed the study, completed animal experiments, performed statistical analysis, analyzed and discussed the results, and prepared, edited, and reviewed the manuscript. Yi-Jin Tang, Zi-Yue Zhang, Qing-Min Meng, Yan Zhang, Jia-Le Deng, Yao Li and Pei-Lin Yang contributed to the literature search, completion of animal experiments, data acquisition and compilation, statistical analysis, analysis and discussion of the results, and manuscript preparation. All authors read and approved the final article. Yu-Jia Tang, Xue Du, Bing Yin, and Hui-Ying Liu contributed equally to this work. Funding This study received financial support from the National Natural Science Foundation of China (No.82372172), the Key Research and Development Plan Project of Heilongjiang Province (No.GA23C007), the Cultivation Project of Heilongjiang Provincial Natural Science Foundation (No.JJ2024LH2132), the Heilongjiang Province Postdoctoral Start-up Fund (No.LBH-Q20037), the Research Project of Heilongjiang Provincial Health Commission (No.20231717010461), the Special Fund for Clinical Research of Wu Jie-Ping Medical Foundation (No.320.6750.2022-02-16), and the 2024 Artificial Liver Special Fund (No.iGandanF-1082024-RGG021). Data Availability The authors are committed to providing the raw data that support the conclusion of this article without any reservation. Declarations Ethics Approval The study protocol was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University (IRB number: LC2024-058). Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yu-Jia Tang, Xue Du, Bing Yin and Hui-Ying Liu contributed equally to this work. Contributor Information Kai Kang, Email: janekk79@126.com. Ming-Yan Zhao, Email: mingyan0927@126.com. Yang Gao, Email: gaoyang0312@126.com. References Associated Data Supplementary Materials Supplementary File 1 (PDF 3.94 MB) Data Availability Statement The authors are committed to providing the raw data that support the conclusion of this article without any reservation.